Vir Biotechnology
CA - San Francisco
Biotechnology1 H-1B visas (FY2023)Focus: Infectious disease therapies
Vir Biotechnology is a life sciences company focused on Infectious disease therapies.
Infectious Diseases
Open Jobs
5
Pipeline & Clinical Trials
A Virtual Prospective Study Exploring Activity Trackers and COVID-19 Infections
Covid19Sotrovimab
Covid19Clinical Trials (1)
NCT05235347Sotrovimab Expanded Access Treatment Protocol (COVID-19)
N/AVRON-0200-AdC6
Chronic Hepatitis BClinical Trials (1)
NCT06070051Dose-Escalation Prime/Boost Therapeutic Vaccination Study Of 2 Chimp Adenoviral Vectors in Adults With Chronic HBV On Nucleos(t)Ide Therapy
Phase 1VIR-2218
Hepatic ImpairmentClinical Trials (1)
NCT05484206Effect of Hepatic Impairment on the Pharmacokinetics and Safety of VIR-2218 and VIR-3434
Phase 1Questionnaire Administration
COVID-19 InfectionClinical Trials (1)
NCT05135650Pharmacokinetics of Sotrovimab as Pre-exposure Prophylaxis for COVID-19 in Hematopoietic Stem Cell Transplant Recipients, COVIDMAB Study
Phase 1sotrovimab
Covid19Clinical Trials (1)
NCT05280717Relative Bioavailability, Safety, and Tolerability of Single-dose Sotrovimab Injection in Adults (COSMIC)
Phase 1sotrovimab
Covid19Clinical Trials (1)
NCT04988152A Study to Investigate the PK, Safety, and Tolerability of Sotrovimab vs Placebo Administered IV or IM in Japanese and Caucasian Participants
Phase 1VIR-1111
HIV I InfectionClinical Trials (1)
NCT04725877VIR-1111: A Prototype Human CMV-based Vaccine for Human Immunodeficiency Virus (HIV) in Healthy Volunteers
Phase 1VIR-2218
Renal ImpairmentClinical Trials (1)
NCT05844228A Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics and Safety of VIR-2218
Phase 1Phase 1
Clinical Trials (1)
NCT05997615Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate Cancer
Phase 1VIR-3434
Chronic Hepatitis BClinical Trials (1)
NCT04423393Study of VIR-3434 in Healthy Volunteers and Patients With Chronic Hepatitis B Virus Infection
Phase 1VIR-5525
Solid Tumor MalignanciesClinical Trials (1)
NCT06960395Safety and Preliminary Efficacy of VIR-5525 and VIR-5525 + Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
Phase 1VIR-2482
Influenza AClinical Trials (1)
NCT04033406Study of VIR-2482 in Healthy Volunteers
Phase 1VIR-2218
Chronic Hepatitis BVIR-3434
Hepatitis B, ChronicClinical Trials (1)
NCT05612581A Platform Study to Evaluate Investigational Therapies in Chronic Hepatitis B Infection
Phase 1/2Phase 1/2
Sotrovimab
COVID-19Clinical Trials (1)
NCT05124210Pharmacokinetics, Pharmacodynamics, and Safety of Single-dose Sotrovimab in High-risk Pediatric Participants With Mild to Moderate COVID-19
Phase 2VIR-2482
Influenza AClinical Trials (1)
NCT05567783A Phase 2 Study to Evaluate the Efficacy and Safety of VIR-2482 for the Prevention of Illness Due to Influenza A
Phase 2VIR-2218
Hepatitis D, ChronicClinical Trials (1)
NCT05461170SOLSTICE: Combination Therapy for the Treatment of Chronic Hepatitis D Infection.
Phase 2Sotrovimab
Covid19Clinical Trials (1)
NCT04779879Safety, Tolerability and Pharmacokinetics of Second Generation VIR-7831 Material in Non-hospitalized Participants With Mild to Moderate COVID-19
Phase 2Phase 2
Clinical Trials (1)
NCT06491563Study to Investigate the Efficacy and Safety of Regimens Containing BRII-179, BRII-835, and PEG-IFNα Treating Chronic Hepatitis B Virus (HBV) Infection (ENRICH)
Phase 2Bamlanivimab
COVID-19Tobevibart
Viral HepatitisClinical Trials (1)
NCT07142811A Study to Evaluate Tobevibart+Elebsiran Versus Bulevirtide in Chronic HDV Infection
Phase 2Tenofovir Alafenamide
Chronic Hepatitis BPEG-IFNα
Chronic Hepatitis B Virus InfectionClinical Trials (1)
NCT05970289Investigate the Efficacy and Safety of BRII-835 (VIR-2218) and PEG-IFNα Combination Therapy in Chronic HBV Patients
Phase 2VIR-2218
Chronic Hepatitis BBRII-835
Hepatitis B, ChronicVIR-2218
Hepatitis B, ChronicClinical Trials (1)
NCT04856085Study of VIR-2218, VIR-3434, and/or PEG-IFNα in Subjects With Chronic Hepatitis B Virus Infection
Phase 2VIR-2218
Hepatitis B, ChronicVIR-7831
Covid19Clinical Trials (1)
NCT04545060VIR-7831 for the Early Treatment of COVID-19 in Outpatients
Phase 2/3Tobevibart
Viral HepatitisClinical Trials (1)
NCT06903338A Study to Evaluate Tobevibart + Elebsiran in Chronic HDV Infection
Phase 3Tobevibart
Viral HepatitisClinical Trials (1)
NCT07128550A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With Bulevirtide
Phase 3sotrovimab
Covid19Clinical Trials (1)
NCT04913675Intramuscular and Intravenous VIR-7831 (Sotrovimab) for Mild/Moderate COVID-19.
Phase 3VIR-7831
COVID-19Clinical Trials (1)
NCT05780281VIR-7831 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)
Phase 3LY3819253
Covid19Open Jobs (5)
Associate Director, External Operations
San Francisco, California, United States
Supply Chain1mo ago
$163K - $228K/yr
Vice President, Business Development
San Francisco, California, United States
Business Development1mo ago
$300K - $345K/yr
Senior Scientist I, Drug Product and Device Development
San Francisco, California, United States
Supply Chain1mo ago
$158K - $199K/yr
Senior Director, Corporate & Scientific Communications
San Francisco, California, United States
Corporate Communications1mo ago
$228K - $318K/yr
Senior Director, IT Infrastructure & Operations
San Francisco, California, United States
Information Technology1mo ago
$236K - $330K/yr
Interview Prep Quick Facts
Portfolio: 26 clinical trials
H-1B (2023): 1 approval
Open Roles: 5 active jobs
Hiring Trend
Stable
5
Open Roles
+0
Added
-0
Filled/Removed
Based on last 4 crawl cycles
Visa Sponsorship
Sponsors Work Visas
H-1B Petitions (FY2023)
1
Approved
0
Denied
100%
Rate
Source: USCIS H-1B Employer Data Hub